FULL TEST BANK FOR PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE A
PRACTICAL APPROACH 5TH EDITION BY VIRGINIA POOLE ARCANGELO, ANDREW
PETERSON, VERONICA WILBUR, TEP M. KANG CHAPTER 1-56 COMPLETE UPDATE
2024/2025
,Contents
Chapter 1 Issues for the Practitioner in Drug Therapy ......................................................................4
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic ........................................5
Chapter 3. Impact of Drug Interactions and Adverse Events on Therapeutics.................................. 15
Chapter 4. Principles of Pharmacotherapy in Children ................................................................... 20
Chapter 5. Principles of Pharmacotherapy in Pregnancy and Lactation........................................... 24
Chapter 6. Principles of Pharmacotherapy in Elderly Patients ........................................................ 30
Chapter 7 Principles of Pharmacotherapy in Pain Management ..................................................... 32
Chapter 8. Principles of Antimicrobial Therapy .............................................................................. 38
Chapter 9. Complementary and Alternative Medicines .................................................................. 42
Chapter 10. Pharmacogenomics .................................................................................................... 46
Chapter 11. Contact Dermatitis ..................................................................................................... 50
Chapter 12. Fungal Infections of the Skin ...................................................................................... 54
Chapter 13 Viral Infections of the Skin .......................................................................................... 57
Chapter 14 Bacterial Infections of the Skin Test Bank .................................................................... 59
Chapter 15. Psoriasis .................................................................................................................... 64
Chapter 16. Acne Vulgaris and Rosacea ......................................................................................... 66
Chapter 17 Ophthalmic Disorders ................................................................................................. 67
Chapter 18. Otitis Media/Externa ................................................................................................. 73
Chapter 19. Hypertension ............................................................................................................. 76
Chapter 20. Hyperlipidemia .......................................................................................................... 81
Chapter 21. Angina ....................................................................................................................... 85
Chapter 22. Heart Failure.............................................................................................................. 91
Chapter 23. Dysrhythmias ............................................................................................................ 95
Chapter 24 Upper Respiratory Infections..................................................................................... 100
Chapter 25. Asthma .................................................................................................................... 102
Chapter 26. Chronic Obstructive Pulmonary Disease ................................................................... 105
Chapter 27. Bronchitis and Pneumonia ....................................................................................... 107
Chapter 28. Nausea and Vomiting ............................................................................................... 110
Chapter 29. Gastroesophageal Reflux Disease and Peptic Ulcer Disease ....................................... 112
Chapter 30. Constipation Diarrhea and Irritable Bowel Syndrome................................................ 116
Chapter 31 Inflammatory Bowel Disease ..................................................................................... 119
Chapter 32. Urinary Tract Infections............................................................................................ 121
,Chapter 34. Overactive Bladder .................................................................................................. 125
Chapter 35. Sexually Transmitted Infections ............................................................................... 127
Chapter 36. Osteoarthritis and Rheumatoid Arthritis................................................................... 130
Chapter 37. Fibromyalgia ............................................................................................................ 133
Chapter 38. Headaches ............................................................................................................... 135
Chapter 39 Seizure Disorders ...................................................................................................... 140
Chapter 40. Depressive Disorders ............................................................................................... 143
Chapter 41. Anxiety Disorders .................................................................................................... 147
Chapter 42 Insomnia and Sleep Disorders ................................................................................... 148
Chapter 43. Attention Deficit/Hyperactivity Disorder Test Bank................................................... 150
Chapter 44. Alzheimer’s Disease ................................................................................................. 151
Chapter 45. Diabetes Mellitus ..................................................................................................... 153
Chapter 46. Thyroid Disorders .................................................................................................... 162
Chapter 47. Allergies and Allergic Reactions ................................................................................ 166
Chapter 48. Human Immunodeficiency Virus ............................................................................... 170
Chapter 49. Coagulation Disturbances ........................................................................................ 174
Chapter 50. Anaemias ................................................................................................................ 177
Chapter 51. Immunizations Chapter 53. Travel Medications ........................................................ 181
Chapter 52. Smoking Cessation ................................................................................................... 186
Chapter 54. Weight Loss ............................................................................................................. 190
Chapter 55. Contraception .......................................................................................................... 193
Chapter 56. Menopause and Menopausal Hormone Therapy....................................................... 196
Chapter 57. Osteoporosis ........................................................................................................... 199
Chapter 58 Vaginitis ................................................................................................................... 201
Chapter 59. The Economics of Pharmacotherapeutics.................................................................. 203
Chapter 60. Integrative Approaches to Pharmacotherapy – A look at Complex Cases ................... 208
,Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
,4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to prescribing
because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
, ANS: A PTS: 1
2. Drugs that have a significant first-pass effect: A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action D. Are converted by
the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the drug.
Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
, C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic effect is
the:
A. Minimum adverse effect level
B. Peak of action
C. Onset of action
D. Therapeutic range
ANS: C PTS: 1
8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A. When the drug has a wide therapeutic range
B. When the drug will be administered for a short time only
C. When there is a high correlation between the dose and saturation of receptor sites D. To
determine if a drug is in the therapeutic range
ANS: D PTS: 1
PRACTICAL APPROACH 5TH EDITION BY VIRGINIA POOLE ARCANGELO, ANDREW
PETERSON, VERONICA WILBUR, TEP M. KANG CHAPTER 1-56 COMPLETE UPDATE
2024/2025
,Contents
Chapter 1 Issues for the Practitioner in Drug Therapy ......................................................................4
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic ........................................5
Chapter 3. Impact of Drug Interactions and Adverse Events on Therapeutics.................................. 15
Chapter 4. Principles of Pharmacotherapy in Children ................................................................... 20
Chapter 5. Principles of Pharmacotherapy in Pregnancy and Lactation........................................... 24
Chapter 6. Principles of Pharmacotherapy in Elderly Patients ........................................................ 30
Chapter 7 Principles of Pharmacotherapy in Pain Management ..................................................... 32
Chapter 8. Principles of Antimicrobial Therapy .............................................................................. 38
Chapter 9. Complementary and Alternative Medicines .................................................................. 42
Chapter 10. Pharmacogenomics .................................................................................................... 46
Chapter 11. Contact Dermatitis ..................................................................................................... 50
Chapter 12. Fungal Infections of the Skin ...................................................................................... 54
Chapter 13 Viral Infections of the Skin .......................................................................................... 57
Chapter 14 Bacterial Infections of the Skin Test Bank .................................................................... 59
Chapter 15. Psoriasis .................................................................................................................... 64
Chapter 16. Acne Vulgaris and Rosacea ......................................................................................... 66
Chapter 17 Ophthalmic Disorders ................................................................................................. 67
Chapter 18. Otitis Media/Externa ................................................................................................. 73
Chapter 19. Hypertension ............................................................................................................. 76
Chapter 20. Hyperlipidemia .......................................................................................................... 81
Chapter 21. Angina ....................................................................................................................... 85
Chapter 22. Heart Failure.............................................................................................................. 91
Chapter 23. Dysrhythmias ............................................................................................................ 95
Chapter 24 Upper Respiratory Infections..................................................................................... 100
Chapter 25. Asthma .................................................................................................................... 102
Chapter 26. Chronic Obstructive Pulmonary Disease ................................................................... 105
Chapter 27. Bronchitis and Pneumonia ....................................................................................... 107
Chapter 28. Nausea and Vomiting ............................................................................................... 110
Chapter 29. Gastroesophageal Reflux Disease and Peptic Ulcer Disease ....................................... 112
Chapter 30. Constipation Diarrhea and Irritable Bowel Syndrome................................................ 116
Chapter 31 Inflammatory Bowel Disease ..................................................................................... 119
Chapter 32. Urinary Tract Infections............................................................................................ 121
,Chapter 34. Overactive Bladder .................................................................................................. 125
Chapter 35. Sexually Transmitted Infections ............................................................................... 127
Chapter 36. Osteoarthritis and Rheumatoid Arthritis................................................................... 130
Chapter 37. Fibromyalgia ............................................................................................................ 133
Chapter 38. Headaches ............................................................................................................... 135
Chapter 39 Seizure Disorders ...................................................................................................... 140
Chapter 40. Depressive Disorders ............................................................................................... 143
Chapter 41. Anxiety Disorders .................................................................................................... 147
Chapter 42 Insomnia and Sleep Disorders ................................................................................... 148
Chapter 43. Attention Deficit/Hyperactivity Disorder Test Bank................................................... 150
Chapter 44. Alzheimer’s Disease ................................................................................................. 151
Chapter 45. Diabetes Mellitus ..................................................................................................... 153
Chapter 46. Thyroid Disorders .................................................................................................... 162
Chapter 47. Allergies and Allergic Reactions ................................................................................ 166
Chapter 48. Human Immunodeficiency Virus ............................................................................... 170
Chapter 49. Coagulation Disturbances ........................................................................................ 174
Chapter 50. Anaemias ................................................................................................................ 177
Chapter 51. Immunizations Chapter 53. Travel Medications ........................................................ 181
Chapter 52. Smoking Cessation ................................................................................................... 186
Chapter 54. Weight Loss ............................................................................................................. 190
Chapter 55. Contraception .......................................................................................................... 193
Chapter 56. Menopause and Menopausal Hormone Therapy....................................................... 196
Chapter 57. Osteoporosis ........................................................................................................... 199
Chapter 58 Vaginitis ................................................................................................................... 201
Chapter 59. The Economics of Pharmacotherapeutics.................................................................. 203
Chapter 60. Integrative Approaches to Pharmacotherapy – A look at Complex Cases ................... 208
,Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
,4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to prescribing
because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
, ANS: A PTS: 1
2. Drugs that have a significant first-pass effect: A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action D. Are converted by
the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the drug.
Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
, C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic effect is
the:
A. Minimum adverse effect level
B. Peak of action
C. Onset of action
D. Therapeutic range
ANS: C PTS: 1
8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A. When the drug has a wide therapeutic range
B. When the drug will be administered for a short time only
C. When there is a high correlation between the dose and saturation of receptor sites D. To
determine if a drug is in the therapeutic range
ANS: D PTS: 1
